BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Joseph Zakrzewski, Amarin's Executive Chairman and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York City. The presentation will take place at 3:30pm ET on September 21, 2011.
A live webcast of the presentation will be available at the following URL: A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.amarincorp.com or by accessing:
http://cc.talkpoint.com/ubsx001/091911a_im/?entity=78_Y5S7L5O
About Amarin
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). Amarin reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [≥500 mg/dL]), as reported on November 29, 2010, and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [≥200 and <500mg/dL] with mixed dyslipidemia), as reported on April 18, 2011. Both the MARINE and ANCHOR trials were conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.